{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T12:51:10Z","timestamp":1770814270382,"version":"3.50.1"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2005,11,1]],"date-time":"2005-11-01T00:00:00Z","timestamp":1130803200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2005,12]]},"DOI":"10.1007\/s00228-005-0032-8","type":"journal-article","created":{"date-parts":[[2005,10,31]],"date-time":"2005-10-31T13:36:31Z","timestamp":1130765791000},"page":"791-795","source":"Crossref","is-referenced-by-count":31,"title":["Pharmacokinetics and pharmacodynamics of etizolam are influenced by polymorphic CYP2C19 activity"],"prefix":"10.1007","volume":"61","author":[{"given":"T.","family":"Fukasawa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Yasui\u2013Furukori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y.","family":"Inoue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Tateishi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Otani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2005,11,1]]},"reference":[{"key":"32_CR1","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/S0278-5846(02)00357-3","volume":"27","author":"T Aoshima","year":"2003","unstructured":"Aoshima T, Fukasawa T, Otsuji Y, Okuyama N, Gerstenberg G, Miura M, Ohkubo T, Sugawara K, Otani K (2003) Effects of the CYP2C19 genotype and cigarette smoking on the single oral dose pharmacokinetics and pharmacodynamics of estazolam. Prog Neuropsychopharmacol Biol Psychiatry 27:535\u2013538","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"32_CR2","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/s00228-004-0789-1","volume":"60","author":"K Araki","year":"2004","unstructured":"Araki K, Yasui\u2013Furukori N, Fukasawa T, Aoshima T, Suzuki A, Inoue Y, Tateishi T, Otani K (2004) Inhibition of the metabolism of etizolam by itraconazole in humans: evidence for the involvement of CYP3A4 in etizolam metabolism. Eur J Clin Pharmacol 60:427\u2013430","journal-title":"Eur J Clin Pharmacol"},{"key":"32_CR3","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1111\/j.1528-1157.1996.tb00021.x","volume":"37","author":"JT Backman","year":"1996","unstructured":"Backman JT, Olkkola KT, Ojala M, Laaksovirta H, Neuvonen PJ (1996) Concentrations and effects of oral midazolam are greatly reduced in patients treated with carbamazepine or phenytoin. Epilepsia 37:253\u2013257","journal-title":"Epilepsia"},{"key":"32_CR4","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1038\/clpt.1989.40","volume":"45","author":"L Bertilsson","year":"1989","unstructured":"Bertilsson L, Henthorn TK, Sanz E, Tybring G, Sawe J, Villen T (1989) Importance of genetic factors in the regulation of diazepam metabolism: relationship to S\u2013mephenytoin, but not debrisoquin, hydroxylation phenotype. Clin Pharmacol Ther 45:348\u2013355","journal-title":"Clin Pharmacol Ther"},{"key":"32_CR5","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1185\/03007999009111650","volume":"12","author":"M Casacchia","year":"1990","unstructured":"Casacchia M, Bolino F, Ecari U (1990) Etizolam in the treatment of generalized anxiety disorder: a double\u2013bind study versus placebo. Curr Med Res Opin 12:215\u2013223","journal-title":"Curr Med Res Opin"},{"key":"32_CR6","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/0009-9236(95)90053-5","volume":"58","author":"SM de Morais","year":"1995","unstructured":"de Morais SM, Goldstein JA, Xie HG, Huang SL, Lu YQ, Xia H, Xiao ZS, Ile N, Zhou HH (1995) Genetic analysis of the S\u2013mephenytoin polymorphism in a Chinese population. Clin Pharmacol Ther 58:404\u2013411","journal-title":"Clin Pharmacol Ther"},{"key":"32_CR7","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1097\/00007691-200410000-00011","volume":"26","author":"T Fukasawa","year":"2004","unstructured":"Fukasawa T, Yasui\u2013Furukori N, Aoshima T, Suzuki A, Tateishi T, Otani K (2004) Single oral dose pharmacokinetics of quazepam is influenced by CYP2C19 activity. Ther Drug Monit 26:529\u2013533","journal-title":"Ther Drug Monit"},{"key":"32_CR8","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/S0893-133X(97)00166-8","volume":"18","author":"H Furukori","year":"1998","unstructured":"Furukori H, Otani K, Yasui N, Kondo T, Kaneko S, Shimoyama R, Ohkubo T, Nagasaki T, Sugawara K (1998) Effect of carbamazepine on the single oral dose pharmacokinetics of alprazolam. Neuropsychopharmacology 18:364\u2013369","journal-title":"Neuropsychopharmacology"},{"key":"32_CR9","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1097\/00004714-200304000-00009","volume":"23","author":"I Gafni","year":"2003","unstructured":"Gafni I, Busto UE, Tyndale EF, Kaplan HL, Sellers EM (2003) The role of cytochrome P450 2C19 activity in flunitrazepam metabolism in vivo. J Clin Psychopharmacol 23:169\u2013175","journal-title":"J Clin Psychopharmacol"},{"key":"32_CR10","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/S0076-6879(96)72025-6","volume":"272","author":"JA Goldstein","year":"1996","unstructured":"Goldstein JA, Blaisdell J (1996) Genetic tests which identify the principal defects in CYP2C19 responsible for the polymorphism in mephenytoin metabolism. Methods Enzymol 272:210\u2013218","journal-title":"Methods Enzymol"},{"key":"32_CR11","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1097\/00008571-199412000-00001","volume":"4","author":"JA Goldstein","year":"1994","unstructured":"Goldstein JA, de Morais SMF (1994) Biochemistry and molecular biology of the human CYP2C subfamily. Pharmacogenetics 4:285\u2013299","journal-title":"Pharmacogenetics"},{"key":"32_CR12","first-page":"354","volume":"19","author":"K Hikida","year":"1990","unstructured":"Hikida K, Inoue Y, Nouchi E, Ohkura Y (1990) Determination of etizolam in human serum or plasma using automated column\u2013switching high\u2013performance liquid chromatography. Jpn J Clin Chem 19:354\u2013359","journal-title":"Jpn J Clin Chem"},{"key":"32_CR13","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1111\/j.1469-8986.1973.tb00801.x","volume":"10","author":"E Hoddes","year":"1973","unstructured":"Hoddes E, Zarcone V, Smythe H, Phillips R, Dement WC (1973) Quantification of sleepiness: a new approach. Psychophysiology 10:413\u2013416","journal-title":"Psychophysiology"},{"key":"32_CR14","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s00228-005-0904-y","volume":"63","author":"S Kondo","year":"2005","unstructured":"Kondo S, Fukasawa T, Yasui\u2013Furukori N, Aoshima T, Suzuki A, Inoue Y, Tateishi T, Otani K (2005) Induction of the metabolism of etizolam by carbamazepine in humans. Eur J Clin Pharmacol 63:185\u2013188","journal-title":"Eur J Clin Pharmacol"},{"key":"32_CR15","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/S0009-9236(96)90214-3","volume":"60","author":"T Kubota","year":"1996","unstructured":"Kubota T, Chiba K, Ishizaki T (1996) Genotyping of S\u2013mephenytoin 4'\u2013hydroxylation in an extended Japanese population. Clin Pharmacol Ther 60:661\u2013666","journal-title":"Clin Pharmacol Ther"},{"key":"32_CR16","unstructured":"Mitsubishi Pharma (2003) Unpublished data in package insert"},{"key":"32_CR17","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1093\/oxfordjournals.jbchem.a022352","volume":"125","author":"M Nakajima","year":"1999","unstructured":"Nakajima M, Yokoi T, Mizutani M, Kinoshita M, Funayama M, Kamataki T (1999) Genetic polymorphism in the 5'\u2013flanking region of human CYP1A2 gene: effect on the CYP1A2 inducibility in humans. J Biochem 125:803\u2013808","journal-title":"J Biochem"},{"key":"32_CR18","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1038\/clpt.1994.60","volume":"55","author":"KT Olkkola","year":"1994","unstructured":"Olkkola KT, Backman JT, Neuvonen PJ (1994) Midazolam should be avoided in patients receiving the systemic antimycotics ketoconazole or itraconazole. Clin Pharmacol Ther 55:481\u2013485","journal-title":"Clin Pharmacol Ther"},{"key":"32_CR19","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/S0893-133X(96)00165-0","volume":"16","author":"K Otani","year":"1997","unstructured":"Otani K, Yasui N, Kaneko S, Ohkubo T, Osanai T, Sugawara K, Hayashi K, Chiba K, Ishizaki T (1997) Effects of genetically determined S\u2013mephenytoin 4\u2013hydroxylation status and cigarette smoking on the single\u2013dose pharmacokinetics of oral alprazolam. Neuropsychopharmacology 16:8\u201314","journal-title":"Neuropsychopharmacology"},{"key":"32_CR20","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/S0009-9236(99)90075-9","volume":"66","author":"XP Qin","year":"1999","unstructured":"Qin XP, Xie HG, Wang W, He N, Huang SL, Xu ZH, Ou\u2013Yang DS, Wang YJ, Zhou HH (1999) Effect of the gene dosage of CYP2C19 on diazepam metabolism in Chinese subjects. Clin Pharmacol Ther 66:642\u2013646","journal-title":"Clin Pharmacol Ther"},{"key":"32_CR21","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1185\/03007999009111500","volume":"12","author":"F Savoldi","year":"1990","unstructured":"Savoldi F, Somenzini G, Ecari U (1990) Etizolam versus placebo in the treatment of panic disorder with agoraphobia: a double\u2013blind study. Curr Med Res Opin 12:185\u2013190","journal-title":"Curr Med Res Opin"},{"key":"32_CR22","first-page":"158","volume":"28","author":"T Tsumagari","year":"19781","unstructured":"Tsumagari T, Nakajima A, Fukuda T, Shuto S, Kenjo T, Morimoto Y, Takigawa Y (1978) Pharmacological properties of 6\u2013(o\u2013chrorophenyl)\u20138\u2013ethyl\u20131\u2013methyl\u20134H\u2013s\u2013triazolo[3,4\u2013c]thieno[2,3\u2013e][1,4]diazepine(Y\u20137131), a new anti\u2013anxiety drug. Arzneimittelforschung 28:1158\u20131178","journal-title":"Arzneimittelforschung"},{"key":"32_CR23","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1038\/clpt.1994.184","volume":"56","author":"A Varhe","year":"1994","unstructured":"Varhe A, Olkkola KT, Neuvonen PJ (1994) Oral triazolam is potentially hazardous to patients receiving systemic antimycotics ketoconazole or itraconazole. Clin Pharmacol Ther 56:601\u2013607","journal-title":"Clin Pharmacol Ther"},{"key":"32_CR24","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1097\/00004714-199806000-00015","volume":"18","author":"K Venkatakrishnan","year":"1998","unstructured":"Venkatakrishnan K, Greenblatt DJ, von Moltke LL, Shader RI (1998) Alprazolam is another substrate for human cytochrome P450\u20133A isoforms. J Clin Psychopharmacol 18:256","journal-title":"J Clin Psychopharmacol"},{"key":"32_CR25","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1097\/00007691-199708000-00001","volume":"19","author":"N Yasui","year":"1997","unstructured":"Yasui N, Otani K, Ohkubo T, Osanai T, Sugawara K, Chiba K, Ishizaki T, Kaneko S (1997) Single\u2013dose pharmacokinetics and pharmacodynamics of oral triazolam in relation to cytochrome P4502C19 (CYP2C19) activity. Ther Drug Monit 19:371\u2013374","journal-title":"Ther Drug Monit"},{"key":"32_CR26","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1007\/s002130050715","volume":"139","author":"N Yasui","year":"1998","unstructured":"Yasui N, Kondo T, Otani K, Furukori H, Kaneko S, Ohkubo T, Osanai T, Nagasaki T, Sugawara K (1998) Effect of itraconazole on the single oral dose pharmacokinetics and pharmacodynamics of alprazolam. Psychopharmacology 139:269\u2013273","journal-title":"Psychopharmacology"},{"key":"32_CR27","volume-title":"Wechsler Adult Intelligence Scale\u2013Revised","author":"D Wechsler","year":"1981","unstructured":"Wechsler D (1981) Wechsler Adult Intelligence Scale\u2013Revised. Harcourt Brace Jovanovich, New York, NY"},{"key":"32_CR28","volume-title":"Biostatistical analysis","author":"JH Zar","year":"1999","unstructured":"Zar JH (1999) Biostatistical analysis, 4th edn. Prentice\u2013Hall, Upper Saddle River, NJ","edition":"4th ed."}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-005-0032-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00228-005-0032-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-005-0032-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,24]],"date-time":"2019-05-24T12:51:17Z","timestamp":1558702277000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00228-005-0032-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,11,1]]},"references-count":28,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2005,12]]}},"alternative-id":["32"],"URL":"https:\/\/doi.org\/10.1007\/s00228-005-0032-8","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,11,1]]}}}